Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family

Rhea-AI Summary

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has secured up to $200,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to expand its revyve™ Antimicrobial Wound Gel product line. The funding, spread over 20 months, will support the development of three new products:

• revyve™ Antimicrobial Wound Gel Spray for sensitive wounds
• revyve™ Antimicrobial Wound Cleanser for various wound types
• Antimicrobial Surgical Gel for surgical/acute wounds

These extensions aim to provide higher price points or volumes, potentially scaling revenues rapidly. The company plans to leverage its expanded FDA 510(k) clearance for the revyve™ Antimicrobial Wound Gel in developing these new products.

Positive

• Secured up to $200,000 in R&D funding from NRC IRAP
• Expanding product line with three new wound care products
• New products expected to command higher prices or generate higher volumes
• Leveraging existing FDA 510(k) clearance for product development
• Potential for rapid revenue scaling with new product line extensions

Negative

• None.

WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to $200,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”).

The funding will be received over a period of 20 months and will support the development of three additional products to build on Kane Biotech’s revyve^TM Antimicrobial Wound Gel technology. The Company expects to be able to leverage its newly expanded US Food and Drug Administration (“FDA”) 510(k) clearance for its revyve^TM Antimicrobial Wound Gel.

(1)	revyveTM Antimicrobial Wound Gel Spray: Will provide ease of use and is optimized for sensitive wounds like first-second degree burns and venous leg ulcers (VLU). The patent pending Gel Spray will allow for contact-free application and removal and will command a higher price per ounce.
(2)	revyveTM Antimicrobial Wound Cleanser: Intended for mechanical cleansing and removal of debris and foreign material from diabetic foot ulcers (DFU), venous leg ulcers (VLU), pressure ulcers (PU), first-second degree burns, skin grafts, and donor sites. Sales targets will be hospitals, ASC, (ambulatory surgery centers), physician offices and HOPD settings where these types of cleansers are used every day. The Wound Rinse has the potential to become Kane’s highest volume product in the revyveTM Antimicrobial Wound Care family.
(3)	Antimicrobial Surgical Gel: A sterilized version of the revyve™ gel for surgical/acute wounds. The product will be applied to all types of surgical wounds and can be used prophylactically on post-surgical incisions as well. Although hospital operating room settings are the initial target for this application, ASC (ambulatory surgery centers), physician offices and HOPD settings are also potential markets. Being sterile, the Surgical Gel will command a significant higher price per ounce.

“We made the strategic decision to ensure that revyve^TM fits within reimbursement as the products are being delivered to patients. These product line extensions will provide either higher price points or higher volumes which will drive our ability to rapidly scale our revenues,” said Marc Edwards, President & CEO. “I would like to thank NRC IRAP for their past and ongoing support of Kane’s research and development.”

Prior support from NRC IRAP has significantly contributed toward the development of Kane Biotech’s quality program infrastructure which led to the Company reaching key milestones in its domestic and global commercialization strategy including ISO 13485:2016 certification, US FDA 510(k) clearance of revyve^TM and most recently its ISO 13485:2016 Medical Device Single Audit Program (MDSAP) Quality Certification.

About Kane Biotech

Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (68 patents and patents pending, trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB^®, coactiv+™, coactiv+^®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information:

Marc Edwards	Ray Dupuis
Chief Executive Officer	Chief Financial Officer
Kane Biotech Inc	Kane Biotech Inc
medwards@kanebiotech.com	rdupuis@kanebiotech.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to Kane’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Kane to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Kane with applicable securities regulatory authorities, available at www.sedarplus.ca. Kane cautions that the foregoing list of factors that may affect future results is not exhaustive.

FAQ

What new products is Kane Biotech (KNBIF) developing with the NRC IRAP funding?

Kane Biotech is developing three new products with the NRC IRAP funding: revyve™ Antimicrobial Wound Gel Spray, revyve™ Antimicrobial Wound Cleanser, and Antimicrobial Surgical Gel.

How much funding did Kane Biotech (KNBIF) receive from NRC IRAP in August 2024?

Kane Biotech received up to $200,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

What is the expected impact of the new products on Kane Biotech's (KNBIF) revenue?

The new product line extensions are expected to provide either higher price points or higher volumes, which Kane Biotech believes will drive its ability to rapidly scale revenues.

What regulatory clearance is Kane Biotech (KNBIF) leveraging for its new product development?

Kane Biotech is leveraging its newly expanded US Food and Drug Administration (FDA) 510(k) clearance for its revyve™ Antimicrobial Wound Gel in developing the new products.